Phase 2 Pancreatitis Trial, Recruiting NCT06080789 Sponsor: Panafina, Inc. Condition: Pancreatitis
Back to Pancreatitis

Phase 2 Pancreatitis Trial, Recruiting

NCT06080789
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with acute pancreatitis (sudden inflammation of the pancreas)
  • Your condition has been assessed as likely to become severe, based on specific criteria set by the study
  • Your condition has not shown meaningful improvement since you were admitted to hospital, as judged by the study doctor
  • You are considered suitable to have the study drug delivered using a specialised camera procedure through your digestive system (confirm with trial site)
  • You have had a recent CT scan or MRI of your abdomen and pancreas available for review by the study team

Who may not be able to join:

  • Your pancreatitis has already been confirmed as severe, meaning you have had serious organ failure lasting more than 48 hours, before entering the study
  • You are expected to be discharged from hospital within 48 hours of joining the study
  • More than 30% of your pancreas shows dead or damaged tissue on your CT scan or MRI
  • You have previously had dead or damaged tissue in your pancreas, including any surgery to remove it
  • You have a history of a long-term form of pancreatitis that causes calcium deposits in the pancreas
  • There are signs that you have an infection or blockage in your bile ducts

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 9194609500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Panafina, Inc.
Registry
ClinicalTrials.gov
Start date
28 June 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇮🇳 India 🇺🇸 United States

Primary endpoints

Number of Participants with Adverse Events; Number of Participants with Serious Adverse Events; Change from Baseline in Clinical Chemistry Parameters; Change from Baseline in Hematology Parameters; Change from Baseline in Vital Signs; Change from Baseline in Pulse Oximetry and Oxygen Delivery Measurements

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov